WOCKHARDT LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹239
- Today's High:
- ₹258.25
- Open Price:
- ₹254.2
- 52W Low:
- ₹145.15
- 52W High:
- ₹315.9
- Prev. Close:
- ₹253.15
- Volume:
- 124460
Company Statistics
- Market Cap.:
- ₹23.13 billion
- Book Value:
- 243.101
- Revenue TTM:
- ₹26.28 billion
- Operating Margin TTM:
- -7.65%
- Gross Profit TTM:
- ₹18.81 billion
- Profit Margin:
- -23.21%
- Return on Assets TTM:
- -1.13%
- Return on Equity TTM:
- -15.52%
Company Profile
WOCKHARDT LTD. had its IPO on under the ticker symbol WOCKPHARMA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. WOCKHARDT LTD. has a staff strength of 4,000 employees.
Stock update
Shares of WOCKHARDT LTD. opened at ₹254.2 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹239 - ₹258.25, and closed at ₹239.85.
This is a -5.25% slip from the previous day's closing price.
A total volume of 124,460 shares were traded at the close of the day’s session.
In the last one week, shares of WOCKHARDT LTD. have slipped by -0.64%.
WOCKHARDT LTD.'s Key Ratios
WOCKHARDT LTD. has a market cap of ₹23.13 billion, indicating a price to book ratio of 0.9331 and a price to sales ratio of 1.148.
In the last 12-months WOCKHARDT LTD.’s revenue was ₹26.28 billion with a gross profit of ₹18.81 billion and an EBITDA of ₹-177500000. The EBITDA ratio measures WOCKHARDT LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, WOCKHARDT LTD.’s operating margin was -7.65% while its return on assets stood at -1.13% with a return of equity of -15.52%.
In Q4, WOCKHARDT LTD.’s quarterly earnings growth was a positive 840.6% while revenue growth was a negative 18.1%.
WOCKHARDT LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-47.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into WOCKHARDT LTD.’s profitability.
WOCKHARDT LTD. stock is trading at a EV to sales ratio of 1.8822 and a EV to EBITDA ratio of -32.4908. Its price to sales ratio in the trailing 12-months stood at 1.148.
WOCKHARDT LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹0
- Total Liabilities
- ₹0
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
WOCKHARDT LTD. ended 2024 with ₹0 in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹0 while shareholder equity stood at ₹0.
WOCKHARDT LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹0 in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
WOCKHARDT LTD.’s total current assets stands at ₹0 while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹0 compared to accounts payable of ₹0 and inventory worth ₹0.
In 2024, WOCKHARDT LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, WOCKHARDT LTD. paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹239.85
- 52-Week High
- ₹315.9
- 52-Week Low
- ₹145.15
- Analyst Target Price
- ₹
WOCKHARDT LTD. stock is currently trading at ₹239.85 per share. It touched a 52-week high of ₹315.9 and a 52-week low of ₹315.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹242.7 and 200-day moving average was ₹207.79 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6259.6% of the company’s stock are held by insiders while 206.3% are held by institutions.
Frequently Asked Questions About WOCKHARDT LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company’s biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.